JP2005522476A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522476A5
JP2005522476A5 JP2003582114A JP2003582114A JP2005522476A5 JP 2005522476 A5 JP2005522476 A5 JP 2005522476A5 JP 2003582114 A JP2003582114 A JP 2003582114A JP 2003582114 A JP2003582114 A JP 2003582114A JP 2005522476 A5 JP2005522476 A5 JP 2005522476A5
Authority
JP
Japan
Prior art keywords
disease
disorder
indan
dibromo
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003582114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522476A (ja
Filing date
Publication date
Priority claimed from GBGB0208384.8A external-priority patent/GB0208384D0/en
Application filed filed Critical
Publication of JP2005522476A publication Critical patent/JP2005522476A/ja
Publication of JP2005522476A5 publication Critical patent/JP2005522476A5/ja
Pending legal-status Critical Current

Links

JP2003582114A 2002-04-11 2003-02-10 新規甲状腺受容体リガンド Pending JP2005522476A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208384.8A GB0208384D0 (en) 2002-04-11 2002-04-11 Novel compounds
PCT/EP2003/001304 WO2003084915A1 (en) 2002-04-11 2003-02-10 Novel thyroid receptor ligands

Publications (2)

Publication Number Publication Date
JP2005522476A JP2005522476A (ja) 2005-07-28
JP2005522476A5 true JP2005522476A5 (cg-RX-API-DMAC7.html) 2006-03-30

Family

ID=9934685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003582114A Pending JP2005522476A (ja) 2002-04-11 2003-02-10 新規甲状腺受容体リガンド

Country Status (10)

Country Link
US (1) US20050171104A1 (cg-RX-API-DMAC7.html)
EP (1) EP1492756A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005522476A (cg-RX-API-DMAC7.html)
KR (1) KR20040102080A (cg-RX-API-DMAC7.html)
CN (1) CN1324001C (cg-RX-API-DMAC7.html)
AU (1) AU2003210234A1 (cg-RX-API-DMAC7.html)
CA (1) CA2481976A1 (cg-RX-API-DMAC7.html)
GB (1) GB0208384D0 (cg-RX-API-DMAC7.html)
IL (1) IL164406A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003084915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501223B2 (en) 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1849465A4 (en) * 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
JP5356831B2 (ja) * 2006-01-26 2013-12-04 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコ科動物の甲状腺機能亢進症を治療するための方法及び組成物
CA2656608C (en) * 2006-07-03 2014-09-16 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
AU2007314405A1 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN105237381A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 5-羟基-1-茚酮的制备方法
CN105330525A (zh) * 2015-10-25 2016-02-17 湖南华腾制药有限公司 7-羟基-1-茚酮的制备方法
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP3683306A4 (en) 2017-09-14 2021-06-09 Riken METHOD FOR MANUFACTURING RETINAGE TISSUE
CN107929273A (zh) * 2017-12-01 2018-04-20 崔坤元 肝脏靶向药物
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
SG11202109855PA (en) 2019-03-13 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
EP4201428A4 (en) 2020-09-11 2024-09-11 Sumitomo Pharma Co., Ltd. MEDIUM FOR TISSUE INTENDED FOR TRANSPLANTATION
JPWO2022054925A1 (cg-RX-API-DMAC7.html) 2020-09-11 2022-03-17
KR20240103018A (ko) 2021-11-19 2024-07-03 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 시트상 망막 조직의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
GB9927056D0 (en) * 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
PL201790B1 (pl) * 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
GB0015205D0 (en) * 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
GB0111861D0 (en) * 2001-05-15 2001-07-04 Karobio Ab Novel compounds

Similar Documents

Publication Publication Date Title
DE02735262T1 (de) Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen
JP2004533450A5 (cg-RX-API-DMAC7.html)
JP2013536855A5 (cg-RX-API-DMAC7.html)
RU2219172C2 (ru) α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ
JP2007502806A5 (cg-RX-API-DMAC7.html)
JP2004529174A5 (cg-RX-API-DMAC7.html)
PT1614418E (pt) Utilização de derivados do ácido (-)(3-tri-halometilfenoxi) (4- halofenil) acético para o tratamento de hiperuricemia
JP2005507381A5 (cg-RX-API-DMAC7.html)
WO2008063842A2 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
JP2005522476A (ja) 新規甲状腺受容体リガンド
ZA200302517B (en) Peroxisome proliferator activated receptor alpha agonists.
CZ282548B6 (cs) Farmaceutický přípravek
RU2003121236A (ru) Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием
RU2007116317A (ru) Гексафторизопропанол-замещенные производные простых эфиров
JP2005521721A5 (cg-RX-API-DMAC7.html)
WO2011020001A2 (en) Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
JP2016514141A5 (cg-RX-API-DMAC7.html)
EP0947496A1 (fr) Composés bicycliques-aromatiques et leur utilisation en médecine humaine ou vétérinaire ainsi qu'en cosmétologie
JP2005532331A5 (cg-RX-API-DMAC7.html)
RU2005109163A (ru) НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPARα И PPARγ
JP2020504120A5 (cg-RX-API-DMAC7.html)
JP2007515467A5 (cg-RX-API-DMAC7.html)
WO1998034909A1 (fr) Composes biaromatiques, compositions les contenant et utilisations
CN1154652A (zh) 去屑组合物
JP2004506037A5 (cg-RX-API-DMAC7.html)